To identify mechanism of resistance and therapeutic strategies to overcome resistance to currently available mTOR inhibitors

Year: 2011
Institution: San Francisco (Contracts & Grants), The Regents of the University of California
Country: United States
State: CA
Award Type: NETRF GRANTS 2005-2017
NET Type: Pancreas
Science Type: Translational

General Description

To test an FDA approved inhibitor of Mek1/2 (FDA approved for melanoma) in preclinical models of neuroendocrine tumors. The results will provide insight into the unique mechanisms that drive neuroendocrine cancer growth. Positive results of an already approved drug could speed the path from the bench-to-bedside to pave the way for clinical trials.

Publication

Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors. Mol Cancer Ther. 2018 Dec;17(12):2702-2709. doi: 10.1158/1535-7163.MCT-17-1204. Epub 2018 Sep 25.